U.S. Markets closed

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
174.54+2.39 (+1.39%)
At close: 4:00PM EDT
People also watch
Full screen
Previous Close172.15
Bid169.00 x 500
Ask175.50 x 200
Day's Range171.71 - 175.06
52 Week Range133.64 - 184.21
Avg. Volume3,388,682
Market Cap127.36B
PE Ratio (TTM)16.58
Earnings DateN/A
Dividend & Yield4.60 (2.67%)
Ex-Dividend Date2017-05-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com16 hours ago

    Court Ruling on 'Biosimilars' Sets Stage for More Drug Acquisitions

    A Supreme Court ruling is likely to stir interest in more than a dozen biosimilars either approved for the market or in later stages of the R&D pipeline.

  • Amgen, Inc. :AMGN-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017
    Capital Cube20 hours ago

    Amgen, Inc. :AMGN-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017

    Categories: Yahoo FinanceGet free summary analysis Amgen, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Amgen, Inc. – GlaxoSmithKline plc Sponsored ADR, Gilead Sciences, Inc., Biogen Inc., Abbott Laboratories and Johnson & Johnson (GSK-US, GILD-US, BIIB-US, ABT-US and JNJ-US) that have also reported for ... Read more (Read more...)

  • Reuters2 days ago

    Amgen gets fast U.S. FDA review for adding heart benefits to cholesterol drug label

    Amgen Inc said on Thursday the U.S. Food and Drug Administration granted priority review to the company's request to add important heart safety data to the label of its expensive injectable cholesterol drug Repatha. The FDA will decide by Dec. 2 whether to allow Amgen to include data from a major clinical trial that showed Repatha significantly cut the risk of heart attack, stroke and death in addition to dramatically lowering bad LDL cholesterol, the company said.